| Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort … A Marabelle, M Fakih, J Lopez, M Shah, R Shapira-Frommer, ... The Lancet Oncology 21 (10), 1353-1365, 2020 | 2009 | 2020 |
| The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity J Canon, K Rex, AY Saiki, C Mohr, K Cooke, D Bagal, K Gaida, T Holt, ... Nature 575 (7781), 217-223, 2019 | 2005 | 2019 |
| Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials RC Doebele, A Drilon, L Paz-Ares, S Siena, AT Shaw, AF Farago, ... The Lancet Oncology 21 (2), 271-282, 2020 | 1608 | 2020 |
| KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors DS Hong, MG Fakih, JH Strickler, J Desai, GA Durm, GI Shapiro, ... New England Journal of Medicine 383 (13), 1207-1217, 2020 | 1543 | 2020 |
| Colon cancer PF Engstrom, JP Arnoletti, AB Benson, YJ Chen, MA Choti, HS Cooper, ... Journal of the National Comprehensive Cancer Network 7 (8), 778-831, 2009 | 896* | 2009 |
| Gastric cancer, version 2.2013 JA Ajani, DJ Bentrem, S Besh, TA D’Amico, P Das, C Denlinger, MG Fakih, ... Journal of the national comprehensive cancer network 11 (5), 531-546, 2013 | 673 | 2013 |
| Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer AB Schrock, C Ouyang, J Sandhu, E Sokol, D Jin, JS Ross, VA Miller, ... Annals of Oncology 30 (7), 1096-1103, 2019 | 623 | 2019 |
| Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study F Meric-Bernstam, H Hurwitz, KPS Raghav, RR McWilliams, M Fakih, ... The Lancet Oncology 20 (4), 518-530, 2019 | 562 | 2019 |
| Metastatic colorectal cancer: current state and future directions MG Fakih Journal of clinical oncology 33 (16), 1809-1824, 2015 | 515 | 2015 |
| Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised … C Eng, TW Kim, J Bendell, G Argilés, NC Tebbutt, M Di Bartolomeo, ... The lancet oncology 20 (6), 849-861, 2019 | 504 | 2019 |
| Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial S Siena, M Di Bartolomeo, K Raghav, T Masuishi, F Loupakis, ... The Lancet Oncology 22 (6), 779-789, 2021 | 346 | 2021 |
| Treatment of metastatic colorectal cancer: ASCO guideline VK Morris, EB Kennedy, NN Baxter, AB Benson III, A Cercek, M Cho, ... Journal of Clinical Oncology 41 (3), 678-700, 2023 | 339 | 2023 |
| Geriatric assessment–driven intervention (GAIN) on chemotherapy-related toxic effects in older adults with cancer: a randomized clinical trial D Li, CL Sun, H Kim, E Soto-Perez-de-Celis, V Chung, M Koczywas, ... JAMA oncology 7 (11), e214158-e214158, 2021 | 336 | 2021 |
| A report of high-dose selenium supplementation: response and toxicities ME Reid, MS Stratton, AJ Lillico, M Fakih, R Natarajan, LC Clark, ... Journal of Trace Elements in Medicine and Biology 18 (1), 69-74, 2004 | 264 | 2004 |
| Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial MG Fakih, S Kopetz, Y Kuboki, TW Kim, PN Munster, JC Krauss, ... The Lancet Oncology 23 (1), 115-124, 2022 | 259 | 2022 |
| Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition DA Fabrizio, TJ George Jr, RF Dunne, G Frampton, J Sun, K Gowen, ... Journal of gastrointestinal oncology 9 (4), 610, 2018 | 248 | 2018 |
| Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the … E Van Cutsem, S Huijberts, A Grothey, R Yaeger, PJ Cuyle, E Elez, ... Journal of clinical oncology 37 (17), 1460-1469, 2019 | 245 | 2019 |
| Trifluridine–tipiracil and bevacizumab in refractory metastatic colorectal cancer GW Prager, J Taieb, M Fakih, F Ciardiello, E Van Cutsem, E Elez, ... New England Journal of Medicine 388 (18), 1657-1667, 2023 | 237 | 2023 |
| Anti-tumor activity of calcitriol: pre-clinical and clinical studies DL Trump, PA Hershberger, RJ Bernardi, S Ahmed, J Muindi, M Fakih, ... The Journal of steroid biochemistry and molecular biology 89, 519-526, 2004 | 234 | 2004 |
| Response to PD-1 blockade in microsatellite stable metastatic colorectal cancer harboring a POLE mutation J Gong, C Wang, PP Lee, P Chu, M Fakih Journal of the National Comprehensive Cancer Network 15 (2), 142-147, 2017 | 229 | 2017 |
